

Supporting information for:

Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools

Victor Sebastian-Perez,^{a,§} Alfonso García-Rubia,^{a,§} Sayed H. Seif el-Din,^b Abdel-Nasser A. Sabra,^b Naglaa M. El-Lakkany,^b Samia William,^c Tom L. Blundell,^d Louis Maes,^e Ana Martinez,^a Nuria E. Campillo,^a Sanaa S. Botros,^{b,*} Carmen Gil^{a,*}

Contents:

- Page S2: Figures S1-S2
- Page S3: Figure S3-S4
- Page S4: Figure S5
- Page S5: Table S1
- Page S6: Table S2
- Page S7: Table S3

^eCentro de Investigaciones Biológicas (CIB-CSIC), Madrid, Spain

^aPharmacology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza 12411, Egypt

^bParasitology Department, Theodor Bilharz Research Institute, Warrak El-Hadar, Imbaba, P.O. Box 30, Giza 12411, Egypt

^dDepartment of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge, CB2 1GA, United Kingdom

^eLaboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Belgium




Figure S1. Metabolic site prediction using SMARTCyp web server for NPD-1246. The atoms in the molecule are ranked according to the probability of being metabolized by the CYP_{2C9}.




Figure S2. Metabolic site prediction using SMARTCyp web server for NPD-1246. The atoms in the molecule are ranked according to the probability of being metabolized by the CYP_{2D6}.




Figure S3. Metabolic site prediction using SMARTCyp web server for NPD-1246. The atoms in the molecule are ranked according to the probability of being metabolized by the CYP_{3A4}.

```

ALDR_HUMAN      MASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQ 60
Q5DD64_SCHJA    -MEPLKMNNGRSIPVIGLGTWNSPPGEVGAAVKKALEIGYRHLDCAYVYRNEAEIGEAL 59
G4LXS0_SCHMA    -MESLKMNNGRSIPVIGLGT[REDACTED]NSPPGEVGVAVKKALEVGYRHLDCAYV[REDACTED]RNEAEIGGALE 59
      . * :*** .:***:*****:*****:* *** *:***:*****:*****:*** ** * *:

ALDR_HUMAN      EKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGK 120
Q5DD64_SCHJA    NALNSLRKREDIFITSKLWNTFFRPEHVRKACEETLKNLRLNYLDLYLIHWVPLKHGG 119
G4LXS0_SCHMA    CSLKSLNLKREDVFTSKL[REDACTED]NTFFRPEHVRKACEETLKNLRLKYLDLYLT[REDACTED]PVPFQYGE 119
      *.. :***:***:***** *:.. * :***:***:***:*****:*****:***: *

ALDR_HUMAN      EFFPLDESGNVVPSDTNILDWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKP 180
Q5DD64_SCHJA    DLFPDTSNGQLCLDNVPHEDTWKEMEKLVDGLVKSIGLSNFNKRQIQNILEHC--RIKP 177
G4LXS0_SCHMA    CL[REDACTED]PTDSNGNFCVDEVPHEETWKEMEKLVDGLVKSIGLSNFNKRQIENILKHC--RIKP 177
      :** *..*.. :.. :** **:****:*****:***:*****: ***: ***: : **

ALDR_HUMAN      AVNQIECHPYLTQEKLQYQCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIKAAK 240
Q5DD64_SCHJA    ANLQIEIHANFPNIKLVYEQSVGLTVTAYAPLGSPA-----SPGKVNLLTKPCVLEIAHR 234
G4LXS0_SCHMA    ANLQIEIHANFPNIQLVEYEQSIGLTVTA[REDACTED]APLGSPA-----SPGRVDLLMEFPWVLQIAKH 234
      * *** * : : :***:*** *:****:***** .* .** .* : ** :

ALDR_HUMAN      HNKTQAQVLIRFPMQRNLVVIPKSVTPERIAENFKVDFDFELSSQDMTTLLSYNRNWRVCA 300
Q5DD64_SCHJA    HKKTPAQVLLRYLLQRKLIVVPKSVTFKRIEENFQVDFDFQLSNEEMHELNTESLNERQFT 294
G4LXS0_SCHMA    HGKTPAQVLLRYLIQRNLIIVPKSVTPKRIEENFGVDFDFQLSKEEMHELNTKGLNERQ[REDACTED]K 294
      * ** *****: :***:***:***** :** *** *****:***:*** * : . * *

ALDR_HUMAN      LLSCTSHKDYPFHFEF 316
Q5DD64_SCHJA    LLQMSGHQEYPFKEEY 310
G4LXS0_SCHMA    LLKMANHSEYPFKDAY 310
      ** . :*.***: :

```

Figure S4. Multiple alignment of the different aldose reductase sequences in the human and in the *Schistosoma* parasite. Key aromatic residues from the catalytic site are highlighted.




Figure S5. Detailed view of the predicted binding mode of compounds **9** (blue), **10** (green) in the *S. mansoni* aldose reductase binding site. A superposition with compound NPD-1246 (yellow) is displayed showing a high degree of similarity.

Table S1. Target ranking obtained according to the PPB results. A list of the 35 best ranking results is shown.

ChEMBL-ID	ChEMBL-Name	Name
1784	GLP1R	Glucagon-like_peptide_1_receptor
1293258	SMAD3	Mothers_against_decapentaplegic_homolog_3
2026	AMPC	Beta-lactamase_AmpC
1075094	NFE2L2	Nuclear_factor_erythroid_2-related_factor_2
1293224	MAPT	Microtubule-associated_protein_tau
2842	TARDB	TAR_DNA-binding_protein_43
2146309	MTOR	Serine/threonine-protein_kinase_mTOR
1741220	CLPP	ATP-dependent_Clp_protease_proteolytic_subunit
614818	BAZ2B	Bromodomain_adjacent_to_zinc_finger_domain_prot ein_2B
2094267	PDE4D	Phosphodiesterase_4
1947	THRB	Thyroid_hormone_receptor_beta-1
2146310	VPR	Aberrant_vpr_protein
1293238	IMPA1	Inositol_monophosphatase_1
4096	TP53	Cellular_tumor_antigen_p53
1293254	FTL	Ferritin_light_chain
4179	MAPK9	c-Jun_N-terminal_kinase_2
2276	MAPK8	c-Jun_N-terminal_kinase_1
240	KCNH2	HERG
275	PDE4B	Phosphodiesterase_4B
4040	MAPK1	MAP_kinaseERK2
4377	GNAS	Guanine_nucleotide-binding protein_G(s),_subunit_alpha
6032	EHMT2	Histone-lysine_N_methyltransferase,_H3_lysine- 9_specific_3
1293278	GMNN	Geminin
1795085	ATXN2	Ataxin-2
5567	NA	Luciferin_4-monooxygenase
1293232	SMN1	Survival_motor_neuron_protein
1075051	DHFR	Dihydrofolate_reductase
2104	P2RX4	P2X_purinoceptor_4
5409	GPBAR1	Gprotein_coupled_bile_acid_receptor_1
3816	PLA2G4A	Cytosolic_phospholipase_A2
3081	AKR1B1	Aldose_reductase
4361	MCL1	Induced_myeloid_leukemia_cell_differentiation_prot ein_Mcl-1
218	CNR1	Cannabinoid_CB1_receptor
1255150	GPBAR1	G-protein_coupled_bile_acid_receptor_1
3563	NA	Cruzipain

Table S2. Target ranking obtained according to the SEA results. A list of the 35 best ranking results is shown.

Target Key	Target Name	Description	p-Value	MaxTC
PGES2_HUMAN+5	PTGES2	Prostaglandin E synthase 2	1.346e-50	0.39
RORB_HUMAN+5	RORB	Nuclear receptor ROR-beta	1.758e-37	0.38
RGS4_HUMAN+5	RGS4	Regulator of G-protein signaling 4	2.607e-35	0.43
HPRK_BACSU+5	hprK	HPr kinase/phosphorylase	8.367e-33	0.33
RGS8_HUMAN+5	RGS8	Regulator of G-protein signalling 8	8.791e-31	0.35
FABI_ECOLI+5	fabI	Enoxyl-(acyl-carrier-protein) reductase (NADH) FabI	7.338e-28	0.32
RORA_HUMAN+5	RORA	Nuclear receptor ROR-alpha	2.818e-27	0.38
DYR_BOVIN+5	DHFR	Dihydrofolate reductase	5.279e-26	0.33
FABP4_HUMAN+5	FABP4	Fatty acid-binding protein adipocyte	1.27e-24	0.44
KCNN2_RAT+5	Kcnn2	Small conductance calcium-activated potassium channel protein 2	5.84e-23	0.31
ALD1_RAT+5	Akr1b7	Aldose reductase-related protein 1	3.998e-21	0.32
TLR7_HUMAN+5	TLR7	Toll-like receptor 7	4.768e-21	0.37
FABI_STAAR+5	fabI	Enoyl-(acyl-carrier-protein) reductase [NADPH] FabI	6.077e-21	0.33
RAD1_HUMAN+5	RAD1	Cell cycle checkpoint protein RAD1	1.718e-17	0.34
AK1A1_HUMAN+5	AKR1A1	Alcohol dehydrogenase [NADP(*)]	3.331e-16	0.32
ALDR_RAT+5	Akr1b1	Aldose reductase	1.665e-15	0.42
PA2GA_HUMAN+5	PLA2G2A	Phospholipase A2, membrane associated	5.44e-15	0.38
PPARG_HUMAN+5	PPARG	Peroxisome proliferator-activated receptor gamma	1.05e-13	0.41
MALX3_YEAST+5	IMA1	Oligo-1,6-glucosidase IMA1	2.858e-13	0.31
FABPH_HUMAN+5	FABP3	Fatty acid-binding protein heart	3.2e-12	0.32
PSA_HUMAN+5	NPEPPS	Puromycin-sensitive aminopeptidase	5.592e-12	0.32
AK1BA_HUMAN+5	AKR1B10	Aldo-keto reductase family 1 member B10	7.999e-12	0.44
ALDR_HUMAN+5	AKR1B1	Aldose reductase	8.602e-12	0.34
FABP5_HUMAN+5	FABP5	Fatty acid-binding protein epidermal	9.502e-12	0.31
P2RX4_HUMAN+5	P2RX4	P2X purinoceptor 4	1.041e-11	0.51
CAC1B_RAT+5	Cacna1b	Voltage-dependent N-type calcium channel subunit alpha-1B	4.116e-11	0.35
BGAL_ECOLX+5	lacZ	Beta-galactosidase	2.645e-10	0.29
PKR1_HUMAN+5	PROKR1	Prokineticin receptor 1	3.503e-10	0.30

SETD7_HUMAN+5	SETD7	Histone-lysine N-methyltransferase SETD7	5.753e-10	0.30
MDHM_HUMAN+5	MDH2	Malate dehydrogenase mitochondrial	6.52e-10	0.36
PD2R2_HUMAN+5	PTGDR 2	Prostaglandin D2 receptor 2	7.745e-10	0.43
AA3R_HUMAN+5	ADORA 3	Adenosine receptor A3	2.644e-09	0.40
EGLN1_HUMAN+5	EGLN1	Egl nine homolog 1	3.855e-09	0.39
PDE8A_HUMAN+5	PDE8A	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	5.204e-09	0.29

Table S3. Validation of the *S. mansoni* model using as a template the aldolase reductase from *S. japonicum* (PDE code 4HBK) considering geometrical and energetical parameters.

QMEAN4	Ramachandran			Verify3D	Errat
	Favoured	Allowed	Outlier		
-0.23	302 (98.1%)	5 (1.6%)	1 (0.3%)	92.9%	93.3%